NCT06828055 - VK2735 for Weight Management Phase 2 (Venture Oral Dosing) | Biotech Hunter

Enrollment

280

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

June 24, 2025

Study Completion Date

August 15, 2025

Conditions

Weight Loss

Interventions

DRUG

Placebo

Matching Placebo to VK2735

DRUG

VK2735

Active Treatment

Trial Locations (15)

32127

Viking Clinical Site #102, Port Orange

33756

Viking Clinical Site #101, Clearwater

33777

Viking Clinical Site #108, Largo

34761

Viking Clinical Site #107, Ocoee

37909

Viking Clinical Site #103, Knoxville

40213

Viking Clinical Site #110, Louisville

46260

Viking Clinical Site #100, Indianapolis

59701

Viking Clinical Site #113, Butte

63303

Viking Clinical Site #109, City of Saint Peters

64131

Viking Clinical Site #112, Kansas City

70072

Viking Clinical Site #114, Marrero

78229

Viking Clinical Site #106, San Antonio

78705

Viking Clinical Site #104, Austin

85381

Viking Clinical Site #111, Peoria

96230

Viking Clinical Site #105, Lake Forest

All Listed Sponsors

lead

Viking Therapeutics, Inc.

INDUSTRY